WCG Clinical
OCTOBER 11, 2024
During the last decade, MRI techniques have been developed which allow noninvasive detection and quantitation of iron in body tissues such as liver, heart, and pancreas. Quantitation of cardiac iron is especially important, as this is the key predictor of cardiac dysfunction and these measurements inform decisions about the effectiveness of iron chelation therapy.
Bio Pharma Dive
OCTOBER 11, 2024
The French pharmaceutical giant said it’s in negotiations to sell a controlling stake of Opella to the private equity firm CD&R, in a deal that reportedly could be worth more than $16 billion.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
OCTOBER 11, 2024
Starboard has accused Pfizer of “coercive conduct” after executives who initially backed the hedge fund retracted their support.
Bio Pharma Dive
OCTOBER 11, 2024
Itovebi is part of a push by Roche to make new inroads in breast cancer. Elsewhere, Turnstone is trimming preclinical research and Gritstone bio is working on a bankruptcy deal.
Speaker: Simran Kaur, Co-founder & CEO at Tattva Health Inc.
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
Pharmaceutical Technology
OCTOBER 11, 2024
Imuldosa is the latest FDA-approved biosimilar of J&J’s blockbuster therapy for the treatment of certain autoimmune diseases.
pharmaphorum
OCTOBER 11, 2024
US Senator Elizabeth Warren asks FTC to scrutinise $16.5bn Novo Holdings/Catalent merger and sale of manufacturing plants to Novo Nordisk.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
pharmaphorum
OCTOBER 11, 2024
FDA gives Roche the first approval for PI3K inhibitor Itovebi, clearing the drug for certain types of advanced breast cancer
Pharmaceutical Technology
OCTOBER 11, 2024
Plaque psoriasis is a chronic condition that affects millions yet is often misunderstood or underappreciated in terms of its broader impact
Pharmaceutical Commerce
OCTOBER 11, 2024
The now-11-year odyssey to track drugs by item through the supply chain will be under a regulatory exemption for up to two years.
Pharmaceutical Technology
OCTOBER 11, 2024
The Cardiovascular and Renal Drugs Advisory Committee voted 10-6 in support of Stealth’s elamipretide for the ultra-rare disorder.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Fierce Pharma
OCTOBER 11, 2024
Six months after scoring FDA approval for hemophilia B gene therapy Beqvez, Pf | For the second time in six months, the FDA approved a Pfizer treatment for hemophilia. On Friday the U.S. regulator signed off on Hympavzi, an anti-tissue factor pathway inhibitor for patients age 12 and older with hemophilia A or B.
Pharmaceutical Technology
OCTOBER 11, 2024
XtalPi's AI biologics discovery platform, XtalFold, has been licensed to Janssen Biotech for advanced biotherapeutics development.
XTalks
OCTOBER 11, 2024
GSK’s latest Phase III AReSVi-006 trial data — presented at the CHEST 2024 Annual Meeting — showed that a single dose of Arexvy (Respiratory Syncytial Virus Vaccine, Adjuvanted) offers sustained protection over three full respiratory syncytial virus (RSV) seasons in adults aged 60 and older, including those at higher risk due to underlying conditions.
Pharmaceutical Technology
OCTOBER 11, 2024
Booster Therapeutics has announced its inception to develop a new class of proteasome activator medicines for neurodegenerative diseases.
BioPharma Reporter
OCTOBER 11, 2024
Jane Koo, head of regulatory affairs at CTMC, plays an important role in accelerating the development and commercialization of innovative cellular therapies.
Pharmaceutical Technology
OCTOBER 11, 2024
High-concentration monoclonal antibodies (mAbs) are gaining prominence given the compliance and cost advantages.
pharmaphorum
OCTOBER 11, 2024
Stay updated on the impact test threshold for England's budget, particularly as it relates to the NHS. Learn how changes may affect healthcare funding and services.
Pharmaceutical Technology
OCTOBER 11, 2024
At CPHI Europe, Angela Vollstedt, global director of Cell & Gene Therapies at Novartis discussed scale up strategies for cell therapies.
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
pharmaphorum
OCTOBER 11, 2024
Building a measurement framework is crucial for assessing the success of digital products. Learn how to create an effective measurement framework for UX to enhance product performance and user satisfaction.
Pharmaceutical Technology
OCTOBER 11, 2024
KeyBioscience and Eli Lilly have extended their partnership to develop a new class of treatments for obesity and associated disorders.
pharmaphorum
OCTOBER 11, 2024
Changing Faces announces the appointment of new board members for Closed Loop Medicine, ARTIDIS, Roche and more in September 2024. Stay updated on the latest developments in these innovative organisations.
Fierce Pharma
OCTOBER 11, 2024
Earlier this year, Evonik unveiled a restructuring project that will result in up to 2,000 layoffs. | After Evonik in March unveiled a restructuring project that will result in up to 2,000 layoffs, the company is now announcing another round of job cuts as it retools portions of its drug ingredients and nutrition businesses.
BioPharma Reporter
OCTOBER 11, 2024
At the forefront of precision dosing, Sharmeen leads DoseMe's efforts to transform personalized medicine from lab research to bedside application.
XTalks
OCTOBER 11, 2024
To mark Breast Cancer Awareness Month, women’s health focused company Hologic has launched a patient education campaign called #BustTheMyth to debunk common myths about breast cancer, mammograms and breast density. The campaign focuses on empowering women with the tools and information they need to fight breast cancer. It emphasizes the importance of early detection and regular screening, a message particularly crucial in light of rising breast cancer rates.
Fierce Pharma
OCTOBER 11, 2024
AstraZeneca has bagged a cardiovascular disease candidate from China's CSPC Pharma in a deal potentially worth $2 billion. | AstraZeneca has bagged a cardiovascular disease candidate from China's CSPC Pharma in a deal potentially worth $2 billion. Astellas is shuffling its cell therapy research team and investing in a dementia gene therapy candidate.
Pharmaceutical Commerce
OCTOBER 11, 2024
The latest news for pharma industry insiders.
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
pharmaphorum
OCTOBER 11, 2024
BIO-Europe™ celebrates 30 years of facilitating partnerships this Fall. In 1994, BIO-Europe launched with the mission to drive biotech innovation and dealmaking forward through one-to-one partnering. Today, it proudly holds the mantle as Europe’s flagship partnering event.
Pharmaceutical Commerce
OCTOBER 11, 2024
Lucy Alexander, capabilities lead, global supply chain and strategy, AstraZeneca, discusses how to handle opposing concerns between supply chain teams and offers communication solutions.
XTalks
OCTOBER 11, 2024
In its latest update on its North Carolina manufacturing facility in the aftermath of Hurricane Helene, Baxter International said it aims to gradually resume production at its North Cove facility in North Carolina. In a securities filing on Wednesday, October 9, Baxter announced the company expects to restore production to 90 percent to 100 percent of the allocated supply for certain intravenous (IV) solution products by the end of 2024.
pharmaphorum
OCTOBER 11, 2024
Rumours that Sanofi was in discussion with private equity groups over the sale of its consumer health business Opella have been confirmed – at least partially.The French pharma group confirmed this morning that it has entered into talks with US-based Clayton Dubilier & Rice to sell a controlling 50% stake in the unit for what has been estimated by Reuters to be in the region of €15 billion ($16.4 billion).
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Expert insights. Personalized for you.
52 
Let's personalize your content